Related Experiment Video
Updated: Aug 12, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Pulmonary infections with respiratory syncytial virus and the parainfluenza viruses
1Department of Pediatrics, University of North Carolina, Chapel Hill 27514.
Insights
Respiratory syncytial virus (RSV) and parainfluenza viruses (PIVs) are major causes of lower respiratory illness in young children. Research focuses on immune responses and developing new immunizations and therapies for these common viral infections.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Respiratory syncytial virus (RSV) and parainfluenza viruses (PIVs) are leading causes of acute lower respiratory illness (LRI) in children under six.
- These paramyxoviruses infect airway epithelium, leading to conditions like croup, bronchitis, and bronchiolitis.
- RSV causes annual winter/spring outbreaks, while PIVs have varied seasonal patterns, with PIV-3 commonly causing croup and bronchiolitis.
Purpose of the Study:
- To understand the immune response to RSV and PIV infections in children.
- To explore the development of novel immunization strategies using viral peptides.
- To review current antiviral therapies for severe RSV infections.
Main Methods:
- Characterization of host immune responses to specific viral antigens.
- Investigation of cell-mediated immunity in controlling established viral infections.
- Review of existing and emerging antiviral treatments for RSV.
Main Results:
- Infection confers short-lived partial resistance, with lifelong susceptibility to reinfection.
- Antibodies in secretions are key for preventing reinfection; cell-mediated immunity resolves existing infections.
- Antiviral therapy is now available for severe RSV cases in infants.
Conclusions:
- Further research into host immune responses is crucial for vaccine development against RSV and PIVs.
- Targeting viral peptides for immunization holds promise for future prevention strategies.
- The availability of antiviral therapy marks a significant advancement in managing severe RSV in infants.
Abstract:
Respiratory syncytial virus (RSV) and the parainfluenza viruses (PIVs) are the most important causes of acute lower respiratory illness (LRI) in infants and children under 6 years of age. These enveloped viruses are members of the paramyxovirus family. They infect cells in the epithelium lining the trachea and intrapulmonary airways, and cause croup, bronchitis, bronchiolitis, and bronchopneumonia. RSV causes annual midwinter to early spring outbreaks of respiratory disease in temperate climates; epidemics are heralded by the appearance of increased numbers of cases of bronchiolitis, primarily in children under 2 years of age. PIV serotypes 1 and 2 cause epidemics of croup in the fall months. Infections with PIV serotype 3 can occur in an endemic pattern throughout the year, or may occur as outbreaks, usually in the fall or spring. Croup and bronchiolitis are the most common syndromes of PIV-3 LRI. Infection with these viruses induces short-lived partial resistance to reinfection, but the human host remains susceptible to reinfection with these agents throughout life. While antibody in respiratory secretions is related most directly to resistance to reinfection, cell-mediated immune responses are crucial for limitation and termination of established infection. Current research efforts are directed at more thorough characterization of the developing host immune response to individual viral antigens, and to development of methods for immunization using specific virion peptides. Recently, antiviral therapy has become available for serious RSV infection in young infants.
More Related Videos
Related Concept Videos
Pulmonary Cycle: Exhalation
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Microbiota of the Respiratory Tract
Influenza
Respiratory Syncytial Virus Disease
Pneumonia I: Introduction

